{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:59:54Z","timestamp":1792299594899,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is a multisystemic hereditary disorder associated with an increased risk of benign and malignant tumor formation predominantly on the skin, bone, and peripheral nervous system. It has been reported that out of all the NF1 cases, more than 95% cases develop the disease due to heterozygous loss-of-function variants in Neurofibromin (<jats:italic>NF1<\/jats:italic>) gene. However, identification of <jats:italic>NF1<\/jats:italic> causative variants by presently recommended method of gene-targeted Sanger sequencing is challenging and cost-intensive due to the large size of the <jats:italic>NF1<\/jats:italic>gene with 60 exons spanning about 350\u00a0kb. Further, conducting the genetic studies is difficult in low resource regions and among families with the limited financial capabilities, restricting them from availing diagnostic as well as proper disease management measures. Here, we studied a three-generation family from Jammu and Kashmir state in India, with multiple affected family members showing clinical indications of NF1. We combinedly used two applications, Whole Exome Sequencing (WES) and Sanger sequencing, for this study and discovered a nonsense variant NM_000267.3:c.2041C&gt;T (NP_000258.1:p.Arg681Ter*) in exon 18 of <jats:italic>NF1<\/jats:italic> gene in a cost effective manner. In silico analyses further substantiated the pathogenicity of this novel variant. The study also emphasized on the role of Next Generation Sequencing (NGS) as a cost-effective method for the discovery of pathogenic variants in disorders with known phenotypes found in large sized candidate genes. The current study is the first study based on the genetic characterization of NF1 from Jammu and Kashmir\u2013India, highlighting the importance of the described methodology adopted for the identification and understanding of the disease in low resource region. The early diagnosis of genetic disorders would open the door to appropriate genetic counseling, reducing the disease burden in the affected families and the general population at large.<\/jats:p>","DOI":"10.1038\/s41598-023-34941-y","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:43:43Z","timestamp":1684158223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effective Whole Exome Sequencing discovers pathogenic variant causing Neurofibromatosis type 1 in a family from Jammu and Kashmir, India"],"prefix":"10.1038","volume":"13","author":[{"given":"Akshi","family":"Spolia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Angural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shipra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Razdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijeshwar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal K.","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarkar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"34941_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0092-8674(90)90253-B","volume":"62","author":"RM Cawthon","year":"1990","unstructured":"Cawthon, R. M. et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193\u2013201 (1990).","journal-title":"Cell"},{"key":"34941_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/(SICI)1096-8628(19991008)86:4<328::AID-AJMG6>3.0.CO;2-O","volume":"86","author":"A Buske","year":"1999","unstructured":"Buske, A. et al. Recurrent NF1 gene mutation in a patient with oligosymptomatic neurofibromatosis type 1 (NF1). Am. J. Med. Genet. 86, 328\u2013330 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"34941_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0030-4220(88)90252-6","volume":"66","author":"JA D'Ambrosio","year":"1988","unstructured":"D\u2019Ambrosio, J. A., Langlais, R. P. & Young, R. S. Jaw and skull changes in neurofibromatosis. Oral Surg. Oral Med. Oral Pathol. 66, 391\u2013396 (1988).","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"34941_CR4","volume-title":"GeneReviews (\u00ae)","author":"J Friedman","year":"1998","unstructured":"Friedman, J. In GeneReviews (\u00ae) Vol. 1 (eds Adam, M. P. et al.) (University of Washington, 1998)."},{"key":"34941_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/gcc.20921","volume":"50","author":"E Beert","year":"2011","unstructured":"Beert, E. et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom. Cancer 50, 1021\u20131032 (2011).","journal-title":"Genes Chromosom. Cancer"},{"key":"34941_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0883073817739509","volume":"33","author":"CJ Campen","year":"2018","unstructured":"Campen, C. J. & Gutmann, D. H. Optic pathway gliomas in neurofibromatosis type 1. J. Child Neurol. 33, 73\u201381 (2018).","journal-title":"J. Child Neurol."},{"key":"34941_CR7","volume":"2019","author":"A Faria","year":"2019","unstructured":"Faria, A. et al. Varstation: a complete and efficient tool to support NGS data analysis. Biorxiv 2019, 833582 (2019).","journal-title":"Biorxiv"},{"key":"34941_CR8","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett, S. W. & Andrews, S. FastQ Screen: A tool for multi-genome mapping and quality control. F1000Research 7, 1338 (2018).","journal-title":"F1000Research"},{"key":"34941_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"34941_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/bioinformatics\/btr174","volume":"27","author":"DW Barnett","year":"2011","unstructured":"Barnett, D. W., Garrison, E. K., Quinlan, A. R., Str\u00f6mberg, M. P. & Marth, G. T. BamTools: A C++ API and toolkit for analyzing and managing BAM files. Bioinformatics 27, 1691\u20131692 (2011).","journal-title":"Bioinformatics"},{"key":"34941_CR11","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/bioinformatics\/btr330","volume":"27","author":"P Danecek","year":"2011","unstructured":"Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156\u20132158 (2011).","journal-title":"Bioinformatics"},{"key":"34941_CR12","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997 (2013)."},{"key":"34941_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinform. 43, 11\u201333 (2013).","journal-title":"Curr. Protoc. Bioinform."},{"key":"34941_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"34941_CR15","unstructured":"Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907 (2012)."},{"key":"34941_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-13-8","volume":"13","author":"D Challis","year":"2012","unstructured":"Challis, D. et al. An integrative variant analysis suite for whole exome next-generation sequencing data. BMC Bioinform. 13, 1\u201312 (2012).","journal-title":"BMC Bioinform."},{"key":"34941_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/bioinformatics\/bty790","volume":"35","author":"C Xu","year":"2019","unstructured":"Xu, C. et al. smCounter2: An accurate low-frequency variant caller for targeted sequencing data with unique molecular identifiers. Bioinformatics 35, 1299\u20131309 (2019).","journal-title":"Bioinformatics"},{"key":"34941_CR18","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164\u2013e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"34941_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013423 (2015).","journal-title":"Genet. Med."},{"key":"34941_CR20","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant review with the integrative genomics viewer. Cancer Res. 77, e31\u2013e34 (2017).","journal-title":"Cancer Res."},{"key":"34941_CR21","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: Predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886\u2013D894 (2019).","journal-title":"Nucleic Acids Res."},{"key":"34941_CR22","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/ng.3703","volume":"48","author":"KA Jagadeesh","year":"2016","unstructured":"Jagadeesh, K. A. et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat. Genet. 48, 1581\u20131586 (2016).","journal-title":"Nat. Genet."},{"key":"34941_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/hmg\/9.2.237","volume":"9","author":"E Ars","year":"2000","unstructured":"Ars, E. et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9, 237\u2013247 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"34941_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/brain\/aws368","volume":"136","author":"ISR Violante","year":"2013","unstructured":"Violante, I. S. R. et al. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: Genotype\u2013phenotype correlations and functional impact. Brain 136, 918\u2013925 (2013).","journal-title":"Brain"},{"key":"34941_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/gtmb.2014.0109","volume":"18","author":"R Maruoka","year":"2014","unstructured":"Maruoka, R. et al. The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: A validation study. Genet. Test. Mol. Biomark. 18, 722\u2013735 (2014).","journal-title":"Genet. Test. Mol. Biomark."},{"key":"34941_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jmoldx.2017.05.001","volume":"19","author":"P Paulo","year":"2017","unstructured":"Paulo, P. et al. Validation of a next-generation sequencing pipeline for the molecular diagnosis of multiple inherited cancer predisposing syndromes. J. Mol. Diagn. 19, 502\u2013513 (2017).","journal-title":"J. Mol. Diagn."},{"key":"34941_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3345\/kjp.2014.57.9.410","volume":"57","author":"MJ Kim","year":"2014","unstructured":"Kim, M. J. & Cheon, C. K. Neurofibromatosis type 1: A single center\u2019s experience in Korea. Korean J. Pediatr. 57, 410 (2014).","journal-title":"Korean J. Pediatr."},{"key":"34941_CR28","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/humu.20826","volume":"29","author":"E Pros","year":"2008","unstructured":"Pros, E. et al. Nature and mRNA effect of 282 different NF1 point mutations: Focus on splicing alterations. Hum. Mutat. 29, E173\u2013E193 (2008).","journal-title":"Hum. Mutat."},{"key":"34941_CR29","first-page":"759","volume":"9","author":"K Li","year":"2016","unstructured":"Li, K. et al. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. Dis. Model. Mech. 9, 759\u2013767 (2016).","journal-title":"Dis. Model. Mech."},{"key":"34941_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1086\/302809","volume":"66","author":"R Fahsold","year":"2000","unstructured":"Fahsold, R. et al. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am. J. Hum. Genet. 66, 790\u2013818 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"34941_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-015-0076-4","volume":"15","author":"M Kocova","year":"2015","unstructured":"Kocova, M., Kochova, E. & Sukarova-Angelovska, E. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: Case report and review of the literature. BMC Endocr. Disord. 15, 1\u20135 (2015).","journal-title":"BMC Endocr. Disord."},{"key":"34941_CR32","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/hmg\/ddw039","volume":"25","author":"JA Toonen","year":"2016","unstructured":"Toonen, J. A. et al. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Hum. Mol. Genet. 25, 1703\u20131713 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"34941_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1086\/519562","volume":"81","author":"O Maertens","year":"2007","unstructured":"Maertens, O. et al. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am. J. Hum. Genet. 81, 243\u2013251 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"34941_CR34","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1136\/jmg.40.6.e82","volume":"40","author":"E Ars","year":"2003","unstructured":"Ars, E. et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J. Med. Genet. 40, e82\u2013e82 (2003).","journal-title":"J. Med. Genet."},{"key":"34941_CR35","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/humu.22392","volume":"34","author":"A Sabbagh","year":"2013","unstructured":"Sabbagh, A. et al. NF 1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: The French experience. Hum. Mutat. 34, 1510\u20131518 (2013).","journal-title":"Hum. Mutat."},{"key":"34941_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/ejhg.2014.145","volume":"23","author":"E Pasmant","year":"2015","unstructured":"Pasmant, E. et al. Neurofibromatosis type 1 molecular diagnosis: What can NGS do for you when you have a large gene with loss of function mutations?. Eur. J. Hum. Genet. 23, 596\u2013601 (2015).","journal-title":"Eur. J. Hum. Genet."},{"key":"34941_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.047753","volume":"44","author":"G Evans","year":"2007","unstructured":"Evans, G. et al. Guidelines for the diagnosis and management of. J. Med. Genet. 44, 81\u201388 (2007).","journal-title":"J. Med. Genet."},{"key":"34941_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/jmg.26.11.704","volume":"26","author":"S Huson","year":"1989","unstructured":"Huson, S., Compston, D., Clark, P. & Harper, P. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J. Med. Genet. 26, 704\u2013711 (1989).","journal-title":"J. Med. Genet."},{"key":"34941_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.29245\/2572-9411\/2016\/2.1017","volume":"1","author":"E Cockey","year":"2016","unstructured":"Cockey, E. & Ullrich, N. J. Neurofibromatosis type 1-associated brain tumors. J. Rare Dis. Res. Treat. 1, 11\u201316 (2016).","journal-title":"J. Rare Dis. Res. Treat."},{"key":"34941_CR40","unstructured":"Upadhyaya, M. The mutational spectrum in neurofibromatosis 1 and its underlying mechanisms. Neurofibromatosis Type 1: From Genotype to Phenotype (1998)."},{"key":"34941_CR41","unstructured":"Graff, J., Coombs, J. & Pramanik, S. (2014)."},{"key":"34941_CR42","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archdermatol.2009.180","volume":"145","author":"VM Riccardi","year":"2009","unstructured":"Riccardi, V. M. Diagnostic and management considerations posed by multiple caf\u00e9 au lait spots. Arch. Dermatol. 145, 929\u2013930 (2009).","journal-title":"Arch. Dermatol."},{"key":"34941_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-014-0333-2","volume":"17","author":"RP Thomas","year":"2015","unstructured":"Thomas, R. P., Gibbs, I. C., Xu, L. W. & Recht, L. Treatment options for optic pathway gliomas. Curr. Treat. Options Neurol. 17, 2 (2015).","journal-title":"Curr. Treat. Options Neurol."},{"key":"34941_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fgene.2020.00415","volume":"11","author":"A Angural","year":"2020","unstructured":"Angural, A. et al. Understanding rare genetic diseases in low resource regions like Jammu and Kashmir-India. Front. Genet. 11, 415 (2020).","journal-title":"Front. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34941-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:47:47Z","timestamp":1684158467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34941-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34941"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34941-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7852"}}